Slingshot members are tracking this event:

BLINCYTO (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
Results From Exploratory Pooled Phase 1 and 2 Analysis Show BLINCYTO, the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S., Induced Complete Remission in Some Patients in all Pre-specified Subgroups
More Than Half of Patients who Achieved Complete Remission Also Experienced Complete Minimal Residual Disease Response
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 03, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Blincyto, Blinatumomab, Acute Lymphoblastic Leukemia